secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-005077
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO Q4 net loss $59.9M ($1.38/share); revenue $31.3M vs $398.7M YoY; cash $565M
--------------------------------------------------------------------------------

- Full-year 2022 net loss $280.3M ($6.50/share) vs net income $127.8M in 2021.
- Revenue fell to $112.7M in 2022 from $470.3M, driven by $370M non-recurring AbbVie collaboration revenue in 2021.
- Zolgensma royalties rose to $101.9M in 2022 from $95.0M in 2021.
- Cash, equivalents and marketable securities $565.2M as of Dec 31, 2022, down from $849.3M; runway into 2025.
- RGX-314 pivotal trials ongoing with BLA expected in 2024; RGX-121 pivotal enrollment to complete H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000095017023005077/0000950170-23-005077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000095017023005077/rgnx-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer